SEC Filings

SEC Filings

Filing date	Form	Description	Filing Group	View
February 11, 2015	10-K	Annual report which provides a comprehensive overview of the company for the past year	Annual Filings	0001144204-15-007770.pdf 0001144204-15-007770.rtf 0001144204-15-007770.xls View HTML
March 23, 2016	10-K	Annual report which provides a comprehensive overview of the company for the past year	Annual Filings	0001144204-16-089697.pdf 0001144204-16-089697.rtf 0001144204-16-089697.xls View HTML
May 12, 2015	10-Q	Quarterly report which provides a continuing view of a company's financial position	Quarterly Filings	0001144204-15-029638.pdf 0001144204-15-029638.rtf 0001144204-15-029638.xls View HTML
August 12, 2015	10-Q	Quarterly report which provides a continuing view of a company's financial position	Quarterly Filings	0001144204-15-048274.pdf 0001144204-15-048274.rtf 0001144204-15-048274.xls View HTML
November 23, 2015	10-Q	Quarterly report which provides a continuing view of a company's financial position	Quarterly Filings	0001144204-15-067423.pdf 0001144204-15-067423.rtf 0001144204-15-067423.xls View HTML
May 12, 2016	10-Q	Quarterly report which provides a continuing view of a company's financial position	Quarterly Filings	0001144204-16-101257.pdf 0001144204-16-101257.rtf 0001144204-16-101257.xls View HTML
March 22, 2013	20-F	Registration of securities of foreign private issuers pursuant to section 12(b) or (g)	Annual Filings	0001144204-13-016759.pdf 0001144204-13-016759.rtf 0001144204-13-016759.xls View HTML
March 24, 2014	20-F	Registration of securities of foreign private issuers pursuant to section 12(b) or (g)	Annual Filings	0001144204-14-017308.pdf 0001144204-14-017308.rtf 0001144204-14-017308.xls View HTML
March 31, 2017	20-F	Registration of securities of foreign private issuers pursuant to section 12(b) or (g)	Annual Filings	0001144204-17-018167.pdf 0001144204-17-018167.rtf 0001144204-17-018167.xls View HTML
July 18, 2018	20-F	Registration of securities of foreign private issuers pursuant to section 12(b) or (g)	Annual Filings	0001144204-18-038891.pdf 0001144204-18-038891.rtf 0001144204-18-038891.xls EX-101.INS - XBRL INSTANCE DOCUMENT View HTML

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.